NYXH vs. INO, XAIR, KRMD, HSAQ, INFU, BVS, ALPA, CLPT, APYX, and CTSO
Should you be buying Nyxoah stock or one of its competitors? The main competitors of Nyxoah include Inovio Pharmaceuticals (INO), Beyond Air (XAIR), KORU Medical Systems (KRMD), Health Sciences Acquisitions Co. 2 (HSAQ), InfuSystem (INFU), Bioventus (BVS), Alpha Healthcare Acquisition Corp. III (ALPA), ClearPoint Neuro (CLPT), Apyx Medical (APYX), and Cytosorbents (CTSO). These companies are all part of the "surgical & medical instruments" industry.
Nyxoah vs.
Nyxoah (NASDAQ:NYXH) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.
Nyxoah has higher earnings, but lower revenue than Inovio Pharmaceuticals. Nyxoah is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Inovio Pharmaceuticals received 705 more outperform votes than Nyxoah when rated by MarketBeat users. Likewise, 73.68% of users gave Inovio Pharmaceuticals an outperform vote while only 42.86% of users gave Nyxoah an outperform vote.
11.5% of Nyxoah shares are owned by institutional investors. Comparatively, 46.4% of Inovio Pharmaceuticals shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by company insiders. Comparatively, 2.0% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Nyxoah has a net margin of -1,270.87% compared to Inovio Pharmaceuticals' net margin of -2,371.71%. Nyxoah's return on equity of -28.01% beat Inovio Pharmaceuticals' return on equity.
In the previous week, Nyxoah and Nyxoah both had 1 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 0.91 beat Nyxoah's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.
Nyxoah presently has a consensus target price of $13.00, suggesting a potential upside of 60.30%. Inovio Pharmaceuticals has a consensus target price of $2.00, suggesting a potential upside of 249.65%. Given Inovio Pharmaceuticals' higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Nyxoah.
Nyxoah has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
Summary
Nyxoah beats Inovio Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NYXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
